TransUnion’s Return On Invested Capital Overview

According to Benzinga Pro, during Q2, TransUnion (NYSE:TRU) earned $99.70 million, a 92.1% increase from the preceding quarter. TransUnion also posted a total of $948.30 million in sales, a 2.93% increase since Q1.

According to Benzinga Pro, during Q2, TransUnion (NYSE:TRU) earned $99.70 million, a 92.1% increase from the preceding quarter. TransUnion also posted a total of $948.30 million in sales, a 2.93% increase since Q1. TransUnion earned $51.90 million, and sales totaled $921.30 million in Q1.

What Is Return On Invested Capital?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company’s ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, TransUnion posted an ROIC of 1.35%.

Keep in mind, while ROIC is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company’s ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q2, TransUnion posted an ROIC of 1.35%.

Keep in mind, while ROIC is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

For TransUnion, the positive return on invested capital ratio of 1.35% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

TransUnion reported Q2 earnings per share at $0.98/share, which beat analyst predictions of $0.97/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results

Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2021.

CARA